As of 2024-07-27, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -1.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 204.75 mil USD. NKTR's TTM EBITDA according to its financial statements is -131.94 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (12.09) - (11.99) | (11.82) |
| Upside | -976.4% - -969.1% | -956.8% |
| Date | EV/EBITDA |
| 2024-07-26 | -1.55 |
| 2024-07-25 | -1.54 |
| 2024-07-24 | -1.59 |
| 2024-07-23 | -1.69 |
| 2024-07-22 | -1.66 |
| 2024-07-19 | -1.57 |
| 2024-07-18 | -1.51 |
| 2024-07-17 | -1.65 |
| 2024-07-16 | -1.68 |
| 2024-07-15 | -1.58 |
| 2024-07-12 | -1.61 |
| 2024-07-11 | -1.52 |
| 2024-07-10 | -1.48 |
| 2024-07-09 | -1.34 |
| 2024-07-08 | -1.36 |
| 2024-07-05 | -1.43 |
| 2024-07-03 | -1.44 |
| 2024-07-02 | -1.26 |
| 2024-07-01 | -1.33 |
| 2024-06-28 | -1.36 |
| 2024-06-27 | -1.22 |
| 2024-06-26 | -1.14 |
| 2024-06-25 | -1.12 |
| 2024-06-24 | -1.26 |
| 2024-06-21 | -1.25 |
| 2024-06-20 | -1.15 |
| 2024-06-18 | -1.22 |
| 2024-06-17 | -1.26 |
| 2024-06-14 | -1.26 |
| 2024-06-13 | -1.37 |
| 2024-06-12 | -1.43 |
| 2024-06-11 | -1.38 |
| 2024-06-10 | -1.31 |
| 2024-06-07 | -1.38 |
| 2024-06-06 | -1.57 |
| 2024-06-05 | -1.61 |
| 2024-06-04 | -1.58 |
| 2024-06-03 | -1.59 |
| 2024-05-31 | -1.40 |
| 2024-05-30 | -1.38 |
| 2024-05-29 | -1.55 |
| 2024-05-28 | -1.72 |
| 2024-05-24 | -1.91 |
| 2024-05-23 | -1.94 |
| 2024-05-22 | -2.07 |
| 2024-05-21 | -2.00 |
| 2024-05-20 | -2.07 |
| 2024-05-17 | -2.07 |
| 2024-05-16 | -2.14 |
| 2024-05-15 | -2.18 |